Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• RA Rheumatoid arthritis
• RA can be categorized as an autoimmune disease.
• MNA malononitrilamide
• FIGS. 1 and 2 show plots of the edema percentage of carrageenan- induced left paw edema after treatment with the drugs indicated.
• the objectives of the present invention include the following: (1) to synthesize a series of novel analogs of leflunomide; (2) to conduct in-vivo studies to evaluate the efficacy of the analogs; and (3) to select the leflunomide analogs that can be used for treating rheumatoid arthritis.
• This invention comprises the syntheses of a series of novel analogs of leflunomide for treating Rheumatoid Arthritis. To the best of our knowledge, these analogs have not been disclosed by any other parties. The in-vivo animal studies indicate that these leflunomide analogs are surpassingly more effective than leflunomide.
• DCC is N,N'-dicyclohexylcarbodiimide and TEA is triethylamine.
• CMC carboxymethyl cellulose
• dexamethone Sigma Chemical Co., USA
• add 5 mL of 1 % CMC solution shake to make the 1.5 mg/mL dexamethasone suspension.
• Carrageenan was used to stimulate the inflammation on the rear left footpad of the rat.
• the inflammation on the left footpad of each rat was measured for rats with and without treatment.
• Treatment includes leflunomide analogs, dexamethasone, ibuprofen, and Malononitrilamide (MNA). Measurements of the inflamation at pre-determined time points were made.
• the rats were weighed and divided into three groups: (1) Control Group, (2) Test Group, and (3) Comparison Group. For each compound, 5 rats were used and marked on the tails. Before injecting carrageenan, the volume of each left footpad was measured (Vo). Each rat was injected in the back as follows: (1) Control Group: 1 % CMC for Control Group,
• V t Volume (mL) of the rear left footpad at "t" time after the injection of
• Dexamethasone 1.5 1. 5 ⁇ 0.7 12 ⁇ 1.8 18.9 ⁇ 1.5 21.1 ⁇ 0.4 21.7 ⁇ 0.4
• Ibuprofen 10 18.9 ⁇ 1.1 26.5 ⁇ 1.4 29.9 ⁇ 0.1 35 ⁇ 0.9 40 ⁇ 0.41
• R is -H, 2-CI, 3-CI, 4-CI, 2,4-(CI) 2 , 2-F, 3-F, 4-F, 2,4-(F) 2 , 2-Br, 3-Br, 4-
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising an effective amount of at least one compound of the formula (I) and/or a physiologically tolerable salt of the compound of the formula (I), in addition to pharmaceutically suitable excipients, additives, and/or active compounds and auxiliaries.
• suitable forms of the pharmaceutical composition are tablets, coated tablets, injectable solutions, suspensions, emulsions, powders, granules,
• Also disclosed is a method of treating rheumatoid arthritis comprising administering to a patient the pharmaceutical composition and one of the drugs on the market already used to treat rheumatoid arthritis comprising dexamethasone, ibuprofen, leflunomide, malononitrilamide, diclofenac sodium, diclofenac potassium, naproxen, or naproxen sodium.
• the present invention provides a series of novel analogs of leflunomide for treating rheumatoid arthritis. The results of animal studies indicate these analogs are surprisingly effective for treating rheumatoid arthritis.
• a method of treating rheumatoid arthritis which comprises administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising the analog.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Rheumatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Pain & Pain Management (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (2)

Family

ID=30115011

Family Applications (1)

Country Status (5)

Cited By (19)

Families Citing this family (5)

Family Cites Families (6)

• 2002
  • 2002-07-15 US US10/195,824 patent/US6727272B1/en not_active Expired - Fee Related
• 2003
  • 2003-06-25 AU AU2003251611A patent/AU2003251611A1/en not_active Abandoned
  • 2003-06-25 EP EP03764320A patent/EP1539143A4/en not_active Withdrawn
  • 2003-06-25 JP JP2004521488A patent/JP2005533104A/ja not_active Ceased
  • 2003-06-25 WO PCT/US2003/019956 patent/WO2004006834A2/en not_active Ceased
• 2010
  • 2010-05-10 JP JP2010108822A patent/JP2010168402A/ja active Pending

Also Published As

Similar Documents

Legal Events